New dry eye treatment shows efficacy in phase 2 trial
January 04, 2022
1 minute read
ST-100, a new dry eye treatment, has shown positive results in a Phase 2 clinical trial, according to a press release from Stuart Therapeutics.
In the multicenter, randomized, controlled, double-blind trial, 160 patients received twice daily doses of 20 mg/mL ST-100, 50 mg/mL ST-100, or placebo.
The 50 mg/mL group met the study’s primary endpoint of Schirmer response rate at 28 days (P = 0.0266). The therapy also demonstrated improvement in several symptoms and ocular staining scores as early as day 7, as well as improvement in overall ocular discomfort by day 14 (P = 0.0332).
The treatment was well tolerated and no serious drug-related adverse events were observed during the trial.
“The Phase 2 trial provided us with an important understanding of the efficacy and tolerability of ST-100 as a topical ophthalmic therapeutic and provided us with a wealth of human data to further explore the details of the mechanism of action and potential of ST.-100 and our collagen mimetic platform technology, PolyCol, in other disease indications,” Eric Schlump, chairman and chief executive officer of Stuart, said in the statement.